2526 logo

Hangzhou Diagens Biotechnology Co., Ltd. Stock Price

SEHK:2526 Community·HK$21.9b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

2526 Share Price Performance

HK$0
-209.60 (-100.00%)
HK$0
-209.60 (-100.00%)
Price HK$0

2526 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with minimal risk.

1 Risk
1 Reward

Hangzhou Diagens Biotechnology Co., Ltd. Key Details

CN¥164.4m

Revenue

CN¥46.3m

Cost of Revenue

CN¥118.1m

Gross Profit

CN¥185.2m

Other Expenses

-CN¥67.1m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-0.76
71.82%
-40.83%
0%
View Full Analysis

About 2526

Founded
2016
Employees
182
CEO
Ning Song
WebsiteView website
www.diagens.com

Hangzhou Diagens Biotechnology Co., Ltd., a medical devices company, develops medical imaging products and services. It operates through Medical Imaging Software and Medical Devices, Technology Licensing, Analysis and Consulting Services, and Others segments. The company’s products portfolio include AI AutoVision, a chromosome karyotype assisted diagnosis and analysis system that provides intelligent karyotyping analysis with applications across genetics and hematologic oncology; MetaSight automatic cell microscopic image scanning system, which enables automated scanning, positioning, image acquisition, and output of chromosome or cell samples for a range of cytogenetics applications, including genetics health, radiation health, and hemato-oncology; and KayoFlow automatic cell harvester for pre-analytical processing of various sample types, including peripheral blood, amniotic fluid, and bone marrow. It also offers KayoFlow integrated slide preparation and staining system for pre-analytical slide preparation and staining of chromosome samples; KayoFlow workflow integration systems; and laboratory reagents and consumables. In addition, the company provides integrated storage, computation, training, and inference localized solutions; and iMed MaaS medical imaging AI platform, a cloud-based service platform. Hangzhou Diagens Biotechnology Co., Ltd. was founded in 2016 and is headquartered in Hangzhou, China.

Recent 2526 News & Updates

Recent updates

No updates